RICT 2024

58th International Conference on Medicinal Chemistry

Interfacing Chemical Biology and Drug Discovery

 Bordeaux, France    July 3-5, 2024

Programme


07:30

Registration

08:45

Opening Ceremony

09:05

Inaugural Lecture (PL01)

Speaker to be announced

Session 1 - RNA Binding Molecules

09:40

Tools and Tactics for Targeting RNA with Small Molecules (PL02)

Dr Jay SCHNEEKLOTH
NATIONAL CANCER INSTITUTE, Frederick, United States
10:15

Small-Molecule Inhibitors of RNA-binding Proteins Regulating m6A RNA Methylation (SL01)

Dr Peng WU
MAX-PLANCK-INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany
10:35

Coffee Break & Exhibition

Session 2 - Breakthroughs in Deep Learning, CryoEM and their Impact on Drug Discovery

11:10

Modern Modelling Techniques to Aid Structure-Based Drug Design (PL03)

Dr Massimiliano BONOMI
INSTITUT PASTEUR, Paris, France
11:45

Cryo-EM at Astrazeneca: Enabling SBDD in Challenging Multiprotein Targets (SL02)

Dr Taiana MAIA DE OLIVEIRA
ASTRAZENECA PLC, Cambridge, United Kingdom
12:05

Lunch, Networking & Exhibition

12:45

Company Workshop by Schrödinger

13:00

Poster session

Session 3 - New Modalities for Drug Discovery

14:30

New Modalities Enabling Target Validation (SL03)

Dr Werngard CZECHTIZKY
ASTRAZENECA, Mölndal, Sweden
14:50

Title to be announced (PL04)

Prof. Akane KAWAMURA
NEWCASTLE UNIVERSITY, Newcastle, United Kingdom
15:25

Molecular Switches for Gene Control (PL05)

Prof. Olalla VÁZQUEZ
PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany
16:00

Coffee Break & Exhibition

Session 4 - Chemistry in Living Systems, Chemical Biology, Including Druggability Assessment

16:35

Gut Feeling: Illuminating Atypical Stress-sensing Mechanisms in the Gut Empowers New Therapeutic Opportunities (PL06)

Prof. Yimon AYE
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland
17:10

Exploring PTM Chemical Biology for Drug Discovery (PL07)

Prof. Edward TATE
IMPERIAL COLLEGE LONDON, London, United Kingdom
17:45

Induced-Volatolomics, a New Research Field in Chemical Biology (SL04)

Dr Pauline POINOT
UNIVERSITY OF POITIERS, Poitiers, France
18:05

Welcome Drink

19:30

End of the Day

Session 5 : Recent Trends in Neurodegenerative Diseases Drug Development

08:45

Toward a Holistic Drug Discovery Approach - How Chemical Biology & Novel Technologies Support the Identification & Development of Drug Candidates (PL08)

Dr Uwe GRETHER
F. HOFFMANN-LA ROCHE, Basel, Switzerland
09:20

Title to be announced (PL09)

Dr Angela MACKAY
NOVARTIS PHARMA AG, Basel, Switzerland
09:55

Design, Synthesis and Evaluation of PET Tracers Targeting alpha-Synuclein, a Rational Approach (PL10)

Prof. Bert WINDHORST
VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands
10:30

Coffee Break & Exhibition

Session 6 - Induced Proximity Including Degraders

11:05

How Degraders Work: Molecular Recognition and Design Principles (PL11)

Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
11:40

Expanding the Chemical Toolbox of E3 Ligase Ligands for PROTAC Design (PL12)

Prof. Michael GUTSCHOW
UNIVERSITY OF BONN, Bonn, Germany
12:15

Discovery of Novel Small Molecules Binders of Soluble Mutant HTT & Derivatization into PROTACs (SL05)

Dr Geoffrey SCHWERTZ
UCB BIOPHARMA, Braine l'Alleud, Belgium
12:35

Lunch, Networking & Exhibition
Career Session

13:15

Company Workshop by WuXi AppTec

13:45

Poster Session

Session 7 - Next Generation Cancer Therapeutics

15:15

Advancements in Drug-like Cyclic Peptides: A Pathway to Orally Available KRAS Inhibitor (PL13)

Dr Satoshi HASHIMOTO
CHUGAI PHARMACEUTICAL, Kanagawa, Japan
15:50

Discovering Novel Inhibitors of Wild-type and Acquired Drug-resistant Mutant Forms of c-MET (SL06)

Dr Gavin W. COLLIE
ASTRAZENECA, Cambridge, United Kingdom

Session 8 - First Disclosures of Clinical Candidates and Cases Studies

16:10

The Discovery of a GPCR Antagonist as Clinical Candidate for Autoimmune Diseases (PL14)

Dr Emmanuel MEYER
ETH, Basel, Switzerland
16:45

Coffee Break & Exhibition

17:20

Galapagos Award For Drug Discovery Chemistry (PL15)

18:05

End of the Day

Session 9 - Enabling Technologies

08:45

Synthetic and Medicinal Chemistry for Biologics (PL16)

Prof. Jeffrey BODE
ETH ZURICH, Zürich, Switzerland
09:20

Recent Advances in DNA-Encoded Library Technologies at GSK (PL17)

Dr Lisa MARCAURELLE
GSK, Cambridge, United States
09:55

Coffee Break & Exhibition

10:30

Vaccines, Antibody Therapies and Diagnostics Based on Synthetic Carbohydrates (PL18)

Prof. Peter H. SEEBERGER
MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany
11:05

Evotec Prize for Excellence in Molecular Design (PL19)

11:50

Closing Ceremony

12:20

End of the Symposium